TICKERNERD
Menu
CDIOCDIOHealthcare · Biotechnology

CDIO Stock Forecast: Cardio Diagnostics Holdings, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.93
−5.17% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$6.0M
Ticker Nerd rank
19 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−3.3%
1M
+24.2%
YTD
−29.0%
1Y
−47.7%
From 52W high
−70.6%
From 52W low
+83.3%
$1.05
$6.55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CDIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardio Diagnostics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Accruals
75
Issuance
48
Quality
37
Growth
30
Revisions
25
Volatility
7
Value
6
Momentum
6

Size (95): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26CDIO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2024BenchmarkReiteratesSpeculative Buy$2.00
6 June 2024BenchmarkMaintainsSpeculative Buy—
19 Apr 2024BenchmarkMaintainsSpeculative Buy—
15 June 2023BenchmarkReiteratesSpeculative Buy—
22 May 2023Northland Capital MarketsInitiatesOutperform—
18 Apr 2023BenchmarkReiteratesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CDIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cardio Diagnostics Holdings, Inc. (CDIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
415.8×

Cheaper than 2% of US stocks

Price / book
0.8×

Cheaper than 79% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−28.3%

Higher than 9% of US stocks

Earnings growth (YoY)
185.1%

Higher than 89% of US stocks

Gross margin
—
Operating margin
−27950.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−75.4%

Higher than 16% of US stocks

Return on assets
−44.1%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CDIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CDIOCardio Diagnostics Holdings, Inc.$6.0M
19
CLGNCollPlant Biotechnologies Ltd.$5.9M
35
PCSAProcessa Pharmaceuticals, Inc.$5.8M
22
CVKDCadrenal Therapeutics, Inc.$5.7M
28
PMCBPharmaCyte Biotech, Inc.$5.7M
39
DRMADermata Therapeutics, Inc.$5.7M
29
ENVBEnveric Biosciences, Inc.$6.4M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardio Diagnostics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDIO news & analysis

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Seeking Alpha · 20 Aug 2026neutral

The news item reports that Cardio Diagnostics Holdings, Inc. (CDIO) discussed precision molecular advances and the use of AI for cardiovascular disease detection, along with strategic growth initiatives, in prepared remarks. This coverage is based on a prepared-remarks transcript published on Seeking Alpha.

Why it matters — A CDIO watcher would care because the prepared remarks outline the company's technology and strategic direction regarding AI-driven cardiovascular detection and growth.

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Business Wire · 18 Aug 2026positive

Cardio Diagnostics announced it has begun in-house test processing at its newly launched, high-complexity CLIA-certified laboratory in Iowa City, Iowa. The lab is now operational for the company's testing operations.

Why it matters — A CDIO watcher would care because establishing this in-house CLIA-certified laboratory represents a milestone in the company's operational capacity for processing its diagnostic tests.

FAQ

Frequently asked questions about CDIO stock

Is CDIO stock a buy right now?

Of the 1 analysts covering Cardio Diagnostics Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardio Diagnostics Holdings, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CDIO?

As at 22 Aug 2026, Cardio Diagnostics Holdings, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the CDIO stock forecast for 2030?

No analyst covering Cardio Diagnostics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDIO are extrapolating price history, which says nothing about the business.

How has CDIO stock performed over the past year?

Cardio Diagnostics Holdings, Inc. returned -47.7% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardio Diagnostics Holdings, Inc. do?

Cardio Diagnostics Holdings Inc. is a biotechnology company in the healthcare sector that develops and commercializes epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management.

What is the latest news on CDIO?

The most recent item we track (Seeking Alpha, 20 Aug 2026): "Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript". The news item reports that Cardio Diagnostics Holdings, Inc. (CDIO) discussed precision molecular advances and the use of AI for cardiovascular disease detection, along with strategic growth initiatives, in prepared remarks. This coverage is based on a prepared-remarks transcript published on Seeking Alpha.

Company

About Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings Inc. is a biotechnology company in the healthcare sector that develops and commercializes epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management. Its primary offerings include Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment blood test targeting events like heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease; and Actionable Clinical Intelligence, a platform delivering epigenetic and genetic insights to clinicians for improved chronic care management. The company also provides CardioInnovate360, a research-use-only solution supporting biopharmaceutical discovery and validation for cardiovascular diseases, and HeartRisk, a SaaS platform offering real-time cardiovascular risk intelligence from aggregated clinical data. Cardio Diagnostics Holdings Inc. serves telemedicine providers, concierge practices, longevity clinics, risk-bearing provider organizations, employer organizations, and correctional facilities, leveraging AI-driven multi-omics technology for personalized molecular insights beyond traditional risk factors. Founded in 2017 and headquartered in Chicago, Illinois, it focuses on making cardiovascular care more accessible and precise.

CEO Dr. Meeshanthini V. Dogan Ph.D. · 15 employees · United States · https://cdio.ai